Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Sales and Marketing
Relax, Celgene investors. The situation isn't all that bad: analyst
Thursday, March 29, 2018
Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.
Pfizer's Xeljanz wins unanimous backing in ulcerative colitis
Friday, March 9, 2018
Pfizer just got some backup on its quest to snag a nod for ulcerative colitis med Xeljanz. On Thursday, an FDA AdComm voted to approve the drug.
Expect AbbVie's story to move to 'Who will it buy?': analyst
Tuesday, January 30, 2018
AbbVie may not seem like the kind of company to chase down mammoth deals. But that doesn’t mean it won’t do just that.
Activists press Alexion for stepped-up guidance, boardroom edits
Friday, December 8, 2017
Industry watchers have tabbed Alexion as a potential activist target. And one prominent activist reportedly wants to take advantage of the opportunity.
Can Vertex be the Gilead of cystic fibrosis?
Thursday, September 28, 2017
Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.
AbbVie, Roche likely to move early on Venclexta expansion in CLL
Tuesday, September 19, 2017
AbbVie and Roche amped up blockbuster hopes for Venclexta, their blood cancer drug, with data pointing the way to a big new approval.
Biogen, AbbVie confront EU action on Zinbryta safety
Monday, July 10, 2017
Biogen and AbbVie’s MS drug Zinbryta faces new restrictions in Europe at a time when tough payers and new challengers are roiling the field.
Pfizer's $14B deal gets more flak after ASCO shortfall
Monday, June 5, 2017
Last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—doesn’t look so impressive anymore, thanks to data rolled out at ASCO.